CLEVELAND - A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs’ Endothelial Corneal Dystrophy (FECD), a disease ...

Bottom Line: Researchers discovered three novel genetic mutations associated with Fuchs endothelial corneal dystrophy, the most common corneal disorder requiring transplantation. Journal in Which the ...

In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a condition in the cornea that subsequently bears his name. The patients ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Fuchs Endothelial Corneal Dystrophy Market - A Global and Regional Analysis: Focus on Treatment Method, End User, and Region - Analysis and Forecast, ...

DUBLIN--(BUSINESS WIRE)--The "Fuchs Endothelial Corneal Dystrophy Market - A Global and Regional Analysis: Focus on Treatment Method, End User, and Region - Analysis and Forecast, 2025-2035" report ...

Fuchs' corneal dystrophy is one of the most common eye diseases diagnosed in almost 5% of the population of Europe aged 40 years or over. It is a hereditary eye disease that causes vision impairment ...

In a new study, researchers at the University of Oregon's Phil and Penny Knight Campus for Accelerating Scientific Impact used start codon disruption with CRISPR-Cas9 gene editing to prevent Fuchs' ...

Diabetes, especially type 1 diabetes, may be a particularly important factor in the etiology of Fuchs endothelial corneal dystrophy (FECD) in findings from a case-control study of about 149.000 US ...

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

(MENAFN- GlobeNewsWire - Nasdaq) The global Fuchs Endothelial Corneal Dystrophy (FECD) market is experiencing robust growth, driven by advancements in corneal transplantation techniques, increased ...